This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how MannKind (MNKD) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
MannKind (MNKD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
MannKind (MNKD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 400% and 15.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy
by Zacks Equity Research
MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how MannKind (MNKD) and Merck (MRK) have performed compared to their sector so far this year.
MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
MannKind (MNKD) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 150% and 13.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Shattuck Labs (STTK) delivered earnings and revenue surprises of 21.28% and 457.50%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 Earnings
by Zacks Equity Research
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 300% and 11.67%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cytokinetics (CYTK) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -87.50% and 98.47%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Key Metrics Tell Us About MannKind (MNKD) Q2 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MannKind (MNKD) Reports Break-Even Earnings for Q2
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 100% and 15.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of 19.35% and 15.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 20% and 8.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.
United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.
Humana (HUM) Rewards Shareholders With a 12.4% Dividend Hike
by Zacks Equity Research
Humana's (HUM) capital position with strong cash-generating abilities and a solid balance sheet will likely sustain its shareholder-friendly moves.
Here's What Could Help MannKind (MNKD) Maintain Its Recent Price Strength
by Zacks Equity Research
MannKind (MNKD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.